ASU Biodesign Scientists Hope to Apply Direct-to-Consumer Model to Proteomics Testing
February 04, 2011
ASU Biodesign Scientists Hope to Apply Direct-to-Consumer Model to Proteomics Testing
The researchers have launched a biotech firm, Healthtell, that aims to use immunosignaturing to develop diagnostics for a variety of indications and potentially enable ongoing monitoring of individuals via mailed-in serum samples.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Researchers ID Gastric Cancer Biomarker Aimed for Use in DTC Tests in US, China
May 6, 2011 / ProteoMonitor - ASU's LaBaer Developing Blood-Based Protein Biomarkers for Early Diagnosis of Breast Cancer
December 24, 2010 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor - Biotech Start-Up Talking20 to Provide DTC Proteomic and Metabolomic Testing
November 2, 2012 / ProteoMonitor - ASU's Biodesign Institute Wins $30M DoD Contract for Immunosignature-Based Pathogen Detection Chip
April 27, 2012 / ProteoMonitor